Might be of interest investors;The development by Novartis, in...

Might be of interest investors;

The development by Novartis, in partnership
with Medicines for Malaria Venture, of Coartem
Dispersible, a paediatric formulation of Coartem,
is thus applauded. Coartem is a combination
of artemether and lumefantrine. Produced as a
sweet-tasting, dispersible tablet designed to ease
administration and improve compliance in children.


In 2001, Novartis committed to make Coartem
available, without profit, to public sector agencies
and malaria-endemic countries under a unique
private-public agreement with WHO. As part of
the product launch, Novartis described its patient
centric approach which involves a training package
for health professionals in appropriate languages,
best practice workshops with National Malaria
Control Programmes and educational materials for
patients. Coartem Dispersible is currently the only
fixed dose combination ACT recommended by
WHO and on the Global Fund Approved List.


---------------------------------------------------------

Robert Sebbag of Sanofi-Aventis is looking to develop new anti-malaria treatments, Sebbag says. We have to be on the ball. Currently we use ACT and it is effective as a treatment but it may become resistant within five years and therefore we have to be ready.

With hundreds of millions of people suffering from malaria and other diseases, there is room for many players, he says. Novartis, for example, is not going to make money with its compound, and neither are we because we sell it (taking a) no-profit/no-loss approach.
source: http://knowledge.insead.edu/contents/healthcare2020.cfm

--------------------------------------------------------
While the poor are unable to afford healthcare or health insurance, Gina Lagomarsino of The Brookings Institution says pharmaceutical companies believe the market for anti-malarial drugs is not profitable enough, even though some 500 million people suffer from the disease.
source: http://knowledge.insead.edu/contents/healthcare2020.cfm

--------------------------------------------------------

Discover s huge number of articles, do a search on malaria and profitability.

It appears Novartis,Sanofi-Aventis and the like have major muscle re distribution and access to funding from the various foundations and NGOs, and we are talking many milions of dollars. Its these foundations NGOs that will be doing the buying/funding and thus far ems have not been able to get a cent.


Nothing is clear cut in this market, you also have the massive problem of counterfeit drugs, the growing resistance to artemether, the ever present threat of patent infringement from lawless countries, the problems with supply of artemether, with novartis the major customer and first in line for scarce supplies, the chinese as the major suppliers with a virtual monopoly, boy oh boy, if you feeling brave do some deeper research on this.

You can begin to understand why nobody has been knocking down eastlands door. You have some pretty heavy hitters that have been in the field for years, you have foundations and NGO's that have a preference to support/fund companies who aren't trying to profit from misery and you have governments and populations with scare resources who can do very little without the support of giant pharma and profit wary Foundations and NGOs. And ems still has a phase 3 to get through..........